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Alzheimer’s disease (AD) is the most common form of dementia among persons over 
65 years of age. It is a brain neurodegenerative disorder characterised by loss of 
memory and cognition. Current treatment is symptomatic, with the major therapeutic 
strategy based on the “cholinergic hypothesis”, specifically acetylcholinesterase 
(AChE) inhibition. Tacrine (THA) was the first and one of the few drugs approved in 
the last decade for the treatment of AD. However, due to the important adverse effects, 
such as hepatotoxicity, it is no longer widely used. Therefore, more potent and less 
aggressive THA analogues are necessary. This prompted us to evaluate the AChE 
inhibitory activity of new oxazole derivatives (compounds 1-5), presenting a pyridine 
ring (compounds 2,3) or a  benzene ring (compounds 4,5) in the molecule (1). The 
biological activity of the compounds was evaluated by measuring the AChE inhibitory 
activity by an adaptation of the method reported by Ellman et al (2). The reaction rates 
were compared and the percent of inhibition by the test compounds was calculated. 
Assays were performed in quadruplicate in at least two independent experiments, and 
THA was used as a reference compound. At the maximum soluble concentrations, 
compounds 1 and 2 inhibited AChE activity by nearly 50%, while the inhibition by the 
derivative 3 was only around 30%. In contrast, the oxazolo-derivatives 4 and 5 were 
devoid of any inhibitory activity, which we can speculate to be due to the absence of 
the N atom in the benzene ring in these compounds. Collectively, these preliminary 
findings point to a potential interest of precursor 1 and THA-derivative 2 for AD 
therapeutics, although structural modifications are needed to improve the solubility of 
the compounds, which is an essential step to enhance their activity. 
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